Using macrophages to improve treatment for glioblastoma
Macrophage-based Therapy and Immune Checkpoint Blockade for Glioblastoma
This study is looking at ways to help people with glioblastoma by changing certain immune cells in the body to fight the tumor better, hoping to make existing treatments work more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10980510 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is resistant to existing therapies. The approach involves reprogramming tumor-associated macrophages, which are immune cells that can either promote or suppress tumor growth. By converting these macrophages from a tumor-promoting state to a tumor-suppressing state, the research aims to enhance the effectiveness of immune checkpoint blockade therapies. The methodology includes screening small molecules that can stimulate macrophage activity to better target and eliminate glioma cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in reprogramming macrophages for cancer therapy, indicating that this approach could be a viable strategy.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Bao, Shideng — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Bao, Shideng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.